R. May

发表

Immunohistochemical characterisation of the IL-13:IL-4Rα axis in the skin of moderate-severe adult atopic dermatitis patients and healthy controls.

J. Lapointe, C. Bruijnzeel-Koomen, M. Sleeman, 2020, The Journal of investigative dermatology.

Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma.

I. Pavord, F. Symon, A. Sousa, 2013, American journal of respiratory and critical care medicine.

Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation

T. Mustelin, C. Brightling, N. Bond, 2015, Nature Communications.

Combinatorial Screening Identifies Novel Promiscuous Matrix Metalloproteinase Activities that Lead to Inhibition of the Therapeutic Target IL-13.

F. Hollfelder, R. Minter, N. Gordon, 2015, Chemistry & biology.

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

I. Pavord, A. Woodcock, Dirk E. Smith, 2015, Thorax.

Development of a mouse model mimicking key aspects of a viral asthma exacerbation.

D. Clarke, M. Sleeman, N. H. Davis, 2014, Clinical science.

A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma

E. Briend, Hongwei Guo, B. Wang, 2014, mAbs.

Sputum biomarkers during acute severe asthma attacks in children—a case‐control study

C. Brightling, D. Thornton, L. Rapley, 2021, Acta paediatrica.

Measurement of eotaxin (CCL11) in induced sputum supernatants: validation and detection in asthma.

R. Djukanović, D. Davies, G. Dent, 2004, The Journal of allergy and clinical immunology.

The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies

T. Mustelin, B. Sellman, M. Sleeman, 2017, The British journal of dermatology.

A Potent Human Anti-Eotaxin1 Antibody, CAT-213: Isolation by Phage Display and in Vitro and in Vivo Efficacy

J. Andrews, T. Vaughan, J. Wilton, 2006, Journal of Pharmacology and Experimental Therapeutics.

Induced sputum and bronchial mucosal expression of interleukin‐13 is not increased in chronic obstructive pulmonary disease

I. Pavord, C. Brightling, P. Bradding, 2008, Allergy.

Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease

I. Pavord, P. Burton, C. Newby, 2015, The Journal of allergy and clinical immunology.

Dectin-2 sensing of house dust mite is critical for the initiation of airway inflammation

M. Sleeman, N. H. Davis, M. Robinson, 2013, Mucosal Immunology.

Serum biomarker profiles suggest that atopic dermatitis is a systemic disease.

T. Mustelin, M. D. de Bruin‐Weller, E. Knol, 2018, The Journal of allergy and clinical immunology.

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients.

M. D. de Bruin‐Weller, E. Knol, B. Giovannone, 2017, The Journal of allergy and clinical immunology.

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

C. Brightling, R. Faggioni, E. Piper, 2012, European Respiratory Journal.

Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma

C. Brightling, R. Faggioni, E. Piper, 2011 .

Strategies targeting the IL-4/IL-13 axes in disease.

M. Fung, R. May, 2015, Cytokine.

Severe exacerbations in moderate-to-severe asthmatics are associated with increased pro-inflammatory and type 1 mediators in sputum and serum

C. Newby, B. Hargadon, C. Brightling, 2019, BMC Pulmonary Medicine.

Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles

I. Pavord, S. Johnston, C. Brightling, 2018, Journal of Allergy and Clinical Immunology.

Increased sputum and bronchial biopsy IL-13 expression in severe asthma.

I. Pavord, A. Morgan, C. Brightling, 2008, The Journal of allergy and clinical immunology.

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

P. O'Byrne, C. Brightling, P. Chanez, 2015, The Lancet. Respiratory medicine.

Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2.

J. Breed, R. Minter, B. Popovic, 2017, Journal of molecular biology.

Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD

C. Brightling, M. Bafadhel, M. Sleeman, 2010, Chest.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial

I. Pavord, A. Woodcock, P. Howarth, 2018, Trials.

Biological exacerbation clusters demonstrate asthma and COPD overlap with distinct mediator and microbiome profiles

I. Pavord, S. Johnston, C. Brightling, 2018 .

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis

T. Mustelin, M. D. de Bruin‐Weller, C. Bruijnzeel-Koomen, 2017, The Journal of allergy and clinical immunology.

IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells.

M. Sleeman, R. Stewart, G. Rosignoli, 2017, Blood advances.

Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus‐predominant subgroup

I. Pavord, C. Brightling, M. Barer, 2019, Allergy.

Sputum Inflammatory Mediators Are Increased in Aspergillus fumigatus Culture-Positive Asthmatics

C. Brightling, A. Wardlaw, L. Rapley, 2016, Allergy, asthma & immunology research.

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

C. Brightling, F. Rose, E. S. Cohen, 2015, Allergy.

Mast cells express IL‐13Rα1: IL‐13 promotes human lung mast cell proliferation and FcɛRI expression

C. Brightling, P. Bradding, P. Monk, 2006, Allergy.